Search details
1.
Polymorphisms of the PD-L1 gene 3'-untranslated region are associated with the expression of PD-L1 in non-small cell lung cancer.
Genes Chromosomes Cancer
; 63(1): e23216, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38169142
2.
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1.
Nat Immunol
; 13(9): 832-42, 2012 Sep.
Article
in English
| MEDLINE | ID: mdl-22842346
3.
EGFR inhibition in EGFR-mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment.
Cancer Sci
; 114(4): 1270-1283, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36529523
4.
Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.
Cancer Sci
; 114(8): 3385-3395, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37208840
5.
Expression of Karyopherin Alpha 2 and Karyopherin Beta 1 Correlate with Poor Prognosis in Gastric Cancer.
Oncology
; 100(12): 685-695, 2022.
Article
in English
| MEDLINE | ID: mdl-36273446
6.
TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance.
Immunity
; 39(6): 1070-81, 2013 Dec 12.
Article
in English
| MEDLINE | ID: mdl-24315994
7.
Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024.
Int J Clin Oncol
; 27(4): 676-683, 2022 Apr.
Article
in English
| MEDLINE | ID: mdl-35092535
8.
Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer.
Eur J Clin Pharmacol
; 77(3): 381-388, 2021 Mar.
Article
in English
| MEDLINE | ID: mdl-33029650
9.
Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
Jpn J Clin Oncol
; 51(5): 753-761, 2021 Apr 30.
Article
in English
| MEDLINE | ID: mdl-33532831
10.
Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Int J Clin Oncol
; 26(1): 51-58, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-32996023
11.
Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
Int J Cancer
; 146(4): 1114-1124, 2020 02 15.
Article
in English
| MEDLINE | ID: mdl-31199520
12.
Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
Cancer Sci
; 111(10): 3926-3937, 2020 Oct.
Article
in English
| MEDLINE | ID: mdl-32772458
13.
A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients.
Cancer Sci
; 111(5): 1685-1691, 2020 May.
Article
in English
| MEDLINE | ID: mdl-32103551
14.
Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome.
Support Care Cancer
; 28(1): 221-227, 2020 Jan.
Article
in English
| MEDLINE | ID: mdl-31016422
15.
Multiplex gene-panel testing for lung cancer patients.
Pathol Int
; 70(12): 921-931, 2020 Dec.
Article
in English
| MEDLINE | ID: mdl-32956529
16.
DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
Cancer Sci
; 110(5): 1599-1608, 2019 May.
Article
in English
| MEDLINE | ID: mdl-30874360
17.
Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Oncologist
; 24(11): e1172-e1179, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31068386
18.
Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0).
Cancer Sci
; 109(9): 2980-2985, 2018 Sep.
Article
in English
| MEDLINE | ID: mdl-30187675
19.
Genomic testing for pancreatic cancer in clinical practice as real-world evidence.
Pancreatology
; 18(6): 647-654, 2018 Sep.
Article
in English
| MEDLINE | ID: mdl-30055942
20.
A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Int J Clin Oncol
; 23(6): 1060-1069, 2018 Dec.
Article
in English
| MEDLINE | ID: mdl-30027464